title: Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry.
abstract: OBJECTIVE
  To investigate the incidence of cancer in arthritis patients treated with or without TNFα inhibitors (TNF-I).
  
  
  METHODS
  Arthritis patients from the DANBIO database were followed-up for cancer in the Danish Cancer Registry during 2000-2008.
  
  
  RESULTS
  Hazard ratio for cancer overall was 1.02 (95% confidence interval (CI) 0.80-1.30) in 3347 TNF-I-treated RA patients compared to non-treated. Excess among TNF-I-treated was found for colon cancer (HR 3.52 (95%CI 1.11-11.15), whereas 6 and 0 ovarian cancer cases were observed in treated and non-treated patients, respectively. Compared to the general population, TNF-I-treated RA patients had increased risk for cancer overall, cancer in lymphatic-haematopoietic tissue and non-melanoma skin cancer, while non-RA patients had no increase in overall cancer risk.
  
  
  CONCLUSIONS
  Our results suggest that TNF-I therapy in routine care is not associated with an overall excess of cancer in arthritis patients, but observed increased risks of colon and ovarian cancer need further investigation.
authors.affiliation: Department of Rheumatology, Gentofte University Hospital, Hellerup, Denmark. lene.dreyer@dadlnet.dk
authors.forename: Lene
authors.initials: L
authors.lastname: Dreyer
authors.forename: Lene
authors.initials: L
authors.lastname: Mellemkjær
authors.forename: Anne Rødgaard
authors.initials: AR
authors.lastname: Andersen
authors.forename: Philip
authors.initials: P
authors.lastname: Bennett
authors.forename: Uta Engling
authors.initials: UE
authors.lastname: Poulsen
authors.forename: Torkell
authors.initials: T
authors.lastname: Juulsgaard Ellingsen
authors.forename: Torben Høiland
authors.initials: TH
authors.lastname: Hansen
authors.forename: Dorte Vendelbo
authors.initials: DV
authors.lastname: Jensen
authors.forename: Louise
authors.initials: L
authors.lastname: Linde
authors.forename: Hanne Merete
authors.initials: HM
authors.lastname: Lindegaard
authors.forename: Anne Gitte Rasmussen
authors.initials: AG
authors.lastname: Loft
authors.forename: Henrik
authors.initials: H
authors.lastname: Nordin
authors.forename: Emina
authors.initials: E
authors.lastname: Omerovic
authors.forename: Claus
authors.initials: C
authors.lastname: Rasmussen
authors.forename: Annette
authors.initials: A
authors.lastname: Schlemmer
authors.forename: Ulrik
authors.initials: U
authors.lastname: Tarp
authors.forename: Merete Lund
authors.initials: ML
authors.lastname: Hetland
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001168:Arthritis / Q000188:drug therapy*; D003718:Denmark / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000139:chemically induced* / Q000453:epidemiology*; D012042:Registries; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha